Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AMED to Fund 9 More Company-Led COVID-19 Drug Projects Including StemRIM, Takeda
September 28, 2020
- MHLW Approves Rakuten’s Photoimmunotherapy, Takeda’s PARP Inhibitor, Gilead’s Jyseleca and More
September 28, 2020
- MHLW to Commence Research on Lasting COVID-19 Effects, Report Ready by March-End
September 28, 2020
- MHLW to Set Up Study Group to Investigate Formulary Initiatives at Hospitals: Pharmaceutical Management Director
September 25, 2020
- MHLW Explains Budget Request to LDP Lawmakers, Members Vigilant about Handling of Price Survey Results
September 25, 2020
- MHLW to Request Budgets for Survey on Prescribing Status, Safety of COVID-19 Meds Using MID-NET Database
September 25, 2020
- Health Minister Ready to Discuss Telemedicine Rollout, but Wants to Ensure Peace of Mind for Patients
September 24, 2020
- PMDA to Continue Remote GCP/Compliance Inspections through End of March 2021
September 24, 2020
- Japan’s COVAX Participation Meant to Confirm Importance of Global Access to Vaccines: Minister
September 23, 2020
- MHLW Grants Orphan Status to 5 APIs
September 23, 2020
- HPV Vaccine Advocate Junko Mihara Picked as Vice MHLW Chief
September 23, 2020
- MHLW Panel Members Call for Special Consideration for Pricing of “Specific-Use Drugs”
September 18, 2020
- MHLW Panel Determines Unmet Medical Needs for 10 Drugs at Its 1st Online Meeting
September 18, 2020
- Health Minister Vows to Gauge Impact on Medical Institutions in Discussing Off-Year Re-Pricing
September 18, 2020
- New Japan PM Sticks to Abe’s Goal to Secure Coronavirus Vaccines for Whole Population by H1 2021
September 17, 2020
- Ex-Health Minister Tamura Comes Back as MHLW Chief
September 16, 2020
- Japan Inks COVAX Pact with Optional Arrangement, Commits 17.2 Billion Yen Upfront
September 16, 2020
- New Vice Health Minister Aiming to Get Coronavirus Drugs and Vaccines to Japanese People “as Quickly as Possible”
September 16, 2020
- MHLW Panel Allows Osaka Univ. Hospital to Continue JANP Study, Requires Report by Year End: Data Scandal
September 15, 2020
- Prioritized Flu Vaccinations for Elderly from October 1, Others Asked to Wait until October 26
September 14, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…